Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells

Anticancer Research

Volumn 21, Issue 5, 2001, Pages 3161-3166

  Scheltema, Johan M W ^a   Romijn, Johan C ^a   Van Steenbrugge, Gert J ^a   Schröder, Fritz H ^a   Mickisch, Gerald H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Bax; Bcl 2; Multidrug resistance; Renal carcinoma; Topoisomerase

Indexed keywords

3 [2 (DIMETHYLAMINO)ETHOXY] 1 HYDROXYBENZO[B]NAPHTHO[2,3 D]FURAN 6,11 DIONE; AMSACRINE; ANTINEOPLASTIC AGENT; CC 313; DAUNORUBICIN; DIMIQ; DNA TOPOISOMERASE (ATP HYDROLYSING); ELSAMICIN A; EPIRUBICIN; ETOPOSIDE; GLYCOPROTEIN P; HOE 33342; IDARUBICIN; INTOPLICINE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; TENIPOSIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; WESTERN BLOTTING;

AMSACRINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, RENAL CELL; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; KIDNEY NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0035569914     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Systemic therapy for renal cell carcinoma
2. Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas
3. Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II
4. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
5. Decreased levels of topoisomerase Ilalpha in human renal cell carcinoma lines resistant to etoposide
6. Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP), glutathione-S-transeferase-(GST-) and topoisomerase II (topo II) genes in renal cell carcinomas and normal kidney
7. Expression of resistance factors (P-glycoprotein, glutathione-S-transferase- and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas
8. P53, Bcl-2, and Bax expression in renal cell carcinoma
9. Biochemical characterisation of elsamicin and other coumarin-related antitumour agents as potent inhibitors of human topoisomerase II
10. Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro
11. Cytotoxic activity of topoisomerase II inhibitors in primary cultures of tumor cells from patients with human hematologic and solid tumors
12. A carboline derivate as a novel mammalian DNA topoisomerase II targeting agent
13. Design of antineoplastic agents on the basis of the "2-phenylnaphtalene-type" structural patern. 2. Synthesis and biological activity studies of benzo[b]naphto[2,3-d]furan-6,11-dione derivatives
14. Application of the MTT assay to human prostate cancer cell lines in vitro: Establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects
15. Quantification of apoptosis and necrosis by flow cytometry
16. Cell death of AKR-2B fibroblasts after serum removal: A process between apoptosis and necrosis
17. Cellular adaptation to drug exposure: Evaluation of the drug-resistant phenotype
18. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP
19. Expression of DNA topoisomerase I in neoplasms of the kidney: Correlation with histological grade, proliferation, and patient survival